Diagnocure Inc (DGCRF) 0.0005 $DGCRF
DiagnoCure announces results of its Annual and Special Meeting of shareholders
PR Newswire - Thu May 19, 4:02PM CDT
DiagnoCure Inc. (TSX: CUR) (OTC Pink: DGCRF) (the "Corporation"
today announced that its shareholders have approved all resolutions presented to them in the Management Proxy Circular dated April 14, 2016 and put forth for vote during the annual and special meeting of the shareholders (the "Meeting" held today in Montreal.
CUR.TO: 0.02 (+0.01)
IIROC Trade Resumption - DiagnoCure Inc.
Newsfile Corp - Fri Apr 15, 11:42AM CDT
full story)
Diagnocure announces its decision to proceed with the voluntary Liquidation and Dissolution of the Corporation
CNW Group - Fri Apr 15, 11:25AM CDT
DiagnoCure Inc. (TSX: CUR) ("DiagnoCure" or the "Corporation" announced today that its board of directors (the "Board" has decided, subject to shareholders approval, to proceed with the voluntary liquidation and dissolution of the Corporation (the "Liquidation" in accordance with the provisions of the Québec's Business Corporation's Act (QBCA), and at a time to be determined by the Board in accordance with a liquidation plan (the "Liquidation Plan" . The Board believes this Liquidation will provide shareholders the best alternative to maximize the value of the remaining assets of the Corporation.
CUR.TO: 0.02 (+0.01)
IIROC Trade Halt - DiagnoCure Inc.
Newsfile Corp - Fri Apr 15, 11:23AM CDT
The following issues have been halted by IIROC:
DiagnoCure Announces First Quarter 2016 Results
CNW Group - Fri Mar 11, 4:05PM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today reported financial and operational results for the first quarter 2016 ended January 31, 2016. The Corporation announced a net loss of $429,655 or $0.01 per share for this quarter. At the end of the quarter, cash and temporary investments stood at $810,726. Operating expenses increased by $88,472, to $563,658 for the first three months of 2016 from $475,186 for the same period of 2015. This increase is attributable primarily to the transaction fees related to the sale of PCA3 to Hologic.
CUR.TO: 0.02 (+0.01), HOLX: 34.10 (-0.04)
DiagnoCure reports recommendations from two independent proxy advisory firms favorable to the PCA3 asset sale and to the reduction of the stated capital
CNW Group - Tue Feb 02, 6:15AM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) ("DiagnoCure" or the "Corporation" is pleased to announce that the proxy advisory firms Institutional Shareholder Services ("ISS" and Glass Lewis & Co. ("Glass Lewis" have both recommended that DiagnoCure shareholders vote FOR the PCA3 asset sale resolution and FOR the reduction of stated capital resolution. Both resolutions are to be considered at the upcoming special meeting of shareholders to be held on February 12, 2016 at 10:00 a.m., Eastern Time, at the offices of McCarthy Tétrault, 1000 de la Gauchetière Street West, Suite 2500, Montréal (Quebec) H3B 0A2.
CUR.TO: 0.02 (+0.01)
DiagnoCure announces fourth quarter 2015 and year-end results as well as proxy circular filing and business initiatives following the execution of an asset purchase agreement to sell all its assets relating to PCA3
PR Newswire - Thu Jan 21, 4:05PM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) ("DiagnoCure" or the "Corporation" today reported financial and operational results for the fourth quarter 2015 and fiscal year ended October 31, 2015. The Corporation announced a net loss of $2,425,901 or $0.05 per share for the fourth quarter ended October 31, 2015, compared to $461,710 or $0.01 per share for the same period in 2014 and a net loss of $3,600,168 or $0.08 per share for fiscal year 2015 compared to $2,032,151 or $0.05 per share for the same period in 2014. Without taking into account the impairment charges of $2,226,672, the net loss for the fourth quarter and fiscal year ended October 31, 2015 would have been respectively $199,229 and $1,373,496. At the end of the quarter, cash and short-term investments stood at $1,108,937 compared to $2,227,326 at the end of fiscal year 2014.
CUR.TO: 0.02 (+0.01)
World Cancer Diagnostic Testing Markets Report 2016
M2 - Wed Jan 20, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/xg6l8p/cancer_diagnostic) has announced the addition of the "Cancer Diagnostic Testing World Markets" report to their offering. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Partial List - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Ambrilia Biopharma, Inc. - AMDL, Inc. - Asuragen, Inc. - Aureon Laboratories, Inc. - Bard Diagnostics, Inc. - Beckman, Dickinson and Company (BD) Diagnostics - TriPath - Beckman Coulter, Inc. - Biocode S.A. - BioCurex - Biomedical Diagnostics - Biomerica - bioMerieux - BioModa, Inc. - Bruker Daltonics - Byk Gulden - Cepheid - Clarient, Inc. - Correlogic Systems, Inc. - CytoCore (formerly Molecular Diagnostics, Inc.) - Cytogen Corporation (now EUSA Pharma) - diaDexus, Inc. - DiagnoCure, Inc. - Diagnostic Automation / Cortez Diagnostics, Inc. - DRG International, Inc. - Eisai Co., Ltd. - Enigma Diagnostics Ltd. - Epigenomics AG - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Gene Logic, Inc. - Gen-Probe, Inc. For more information visit http://www.researchandmarkets.com/research/xg...diagnostic
EXAS: 10.00 (-0.84), AFFX: 14.01 (+0.02), CPHD: 28.77 (-1.02)
DiagnoCure announces third quarter 2015 results
PR Newswire - Fri Sep 11, 6:30AM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today reported financial and operational results for the third quarter ended July 31, 2015. The Corporation announced a net loss of $274,005 or $0.01 per share for this quarter. At the end of the quarter, cash and temporary investments stood at $1,231,626. Operating expenses decreased by $250,683, to $406,846 for the third quarter of 2015 from $657,529 for the same period of 2014. The net loss before non-cash elements decreased by 54%, from $406,853 for the third quarter of 2014 to $186,335 for the same period of 2015. These decreases are attributable primarily to the reduction of operating expenses implemented in the first quarter of 2015.
CUR.TO: 0.02 (+0.01)
DiagnoCure announces second quarter 2015 results and restructures its Board of directors
CNW Group - Fri Jun 12, 6:30AM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today reported financial and operational results for the second quarter ended April 30, 2015. The Corporation announced a net loss of $567,991 or $0.01 per share for this quarter. At the end of the quarter, cash and temporary investments stood at $1,574,957. Operating expenses, before restructuring charges of $188,964, decreased by $158,278, to $508,812 for the second quarter of 2015 from $667,090 for the same period of 2014. The net loss before non-cash elements and restructuring charges decreased by a third, from $431,706 for the second quarter of 2014 to $289,228 for the same period of 2015. These decreases are attributable primarily to the reduction of operating expenses implemented in the first quarter of 2015.
CUR.TO: 0.02 (+0.01)
DiagnoCure's new prostate cancer multimarker urine test featured at a recent press event of the American Urological Association
CNW Group - Wed May 20, 4:01PM CDT
DiagnoCure Inc. (TSX: CUR; OTCQX: DGCRF) (the "Corporation" today reports that the results of the prospective trial on its prostate cancer panel (PCP) urine test were well received by the urologist community attending the 2015 Annual Meeting of the American Urological Association (AUA) held from May 15 to May 19 in New Orleans, Louisiana.
CUR.TO: 0.02 (+0.01)
DiagnoCure announces results of its Annual and General Meeting of shareholders
CNW Group - Thu Apr 30, 5:30PM CDT
DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today announced that its shareholders have approved all resolutions presented to them in the Management Proxy Circular dated March 5, 2015 and put forth for vote during the shareholders meeting held today in Montreal.
CUR.TO: 0.02 (+0.01)
DiagnoCure announces results of its Annual and Special Meeting of shareholders
PR Newswire - Thu May 19, 4:02PM CDT
DiagnoCure Inc. (TSX: CUR) (OTC Pink: DGCRF) (the "Corporation"
today announced that its shareholders have approved all resolutions presented to them in the Management Proxy Circular dated April 14, 2016 and put forth for vote during the annual and special meeting of the shareholders (the "Meeting" held today in Montreal. CUR.TO: 0.02 (+0.01)
IIROC Trade Resumption - DiagnoCure Inc.
Newsfile Corp - Fri Apr 15, 11:42AM CDT
full story)
Diagnocure announces its decision to proceed with the voluntary Liquidation and Dissolution of the Corporation
CNW Group - Fri Apr 15, 11:25AM CDT
DiagnoCure Inc. (TSX: CUR) ("DiagnoCure" or the "Corporation"
announced today that its board of directors (the "Board" has decided, subject to shareholders approval, to proceed with the voluntary liquidation and dissolution of the Corporation (the "Liquidation" in accordance with the provisions of the Québec's Business Corporation's Act (QBCA), and at a time to be determined by the Board in accordance with a liquidation plan (the "Liquidation Plan" . The Board believes this Liquidation will provide shareholders the best alternative to maximize the value of the remaining assets of the Corporation. CUR.TO: 0.02 (+0.01)
IIROC Trade Halt - DiagnoCure Inc.
Newsfile Corp - Fri Apr 15, 11:23AM CDT
The following issues have been halted by IIROC:
DiagnoCure Announces First Quarter 2016 Results
CNW Group - Fri Mar 11, 4:05PM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today reported financial and operational results for the first quarter 2016 ended January 31, 2016. The Corporation announced a net loss of $429,655 or $0.01 per share for this quarter. At the end of the quarter, cash and temporary investments stood at $810,726. Operating expenses increased by $88,472, to $563,658 for the first three months of 2016 from $475,186 for the same period of 2015. This increase is attributable primarily to the transaction fees related to the sale of PCA3 to Hologic. CUR.TO: 0.02 (+0.01), HOLX: 34.10 (-0.04)
DiagnoCure reports recommendations from two independent proxy advisory firms favorable to the PCA3 asset sale and to the reduction of the stated capital
CNW Group - Tue Feb 02, 6:15AM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) ("DiagnoCure" or the "Corporation"
is pleased to announce that the proxy advisory firms Institutional Shareholder Services ("ISS" and Glass Lewis & Co. ("Glass Lewis" have both recommended that DiagnoCure shareholders vote FOR the PCA3 asset sale resolution and FOR the reduction of stated capital resolution. Both resolutions are to be considered at the upcoming special meeting of shareholders to be held on February 12, 2016 at 10:00 a.m., Eastern Time, at the offices of McCarthy Tétrault, 1000 de la Gauchetière Street West, Suite 2500, Montréal (Quebec) H3B 0A2. CUR.TO: 0.02 (+0.01)
DiagnoCure announces fourth quarter 2015 and year-end results as well as proxy circular filing and business initiatives following the execution of an asset purchase agreement to sell all its assets relating to PCA3
PR Newswire - Thu Jan 21, 4:05PM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) ("DiagnoCure" or the "Corporation"
today reported financial and operational results for the fourth quarter 2015 and fiscal year ended October 31, 2015. The Corporation announced a net loss of $2,425,901 or $0.05 per share for the fourth quarter ended October 31, 2015, compared to $461,710 or $0.01 per share for the same period in 2014 and a net loss of $3,600,168 or $0.08 per share for fiscal year 2015 compared to $2,032,151 or $0.05 per share for the same period in 2014. Without taking into account the impairment charges of $2,226,672, the net loss for the fourth quarter and fiscal year ended October 31, 2015 would have been respectively $199,229 and $1,373,496. At the end of the quarter, cash and short-term investments stood at $1,108,937 compared to $2,227,326 at the end of fiscal year 2014. CUR.TO: 0.02 (+0.01)
World Cancer Diagnostic Testing Markets Report 2016
M2 - Wed Jan 20, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/xg6l8p/cancer_diagnostic) has announced the addition of the "Cancer Diagnostic Testing World Markets" report to their offering. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Partial List - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Ambrilia Biopharma, Inc. - AMDL, Inc. - Asuragen, Inc. - Aureon Laboratories, Inc. - Bard Diagnostics, Inc. - Beckman, Dickinson and Company (BD) Diagnostics - TriPath - Beckman Coulter, Inc. - Biocode S.A. - BioCurex - Biomedical Diagnostics - Biomerica - bioMerieux - BioModa, Inc. - Bruker Daltonics - Byk Gulden - Cepheid - Clarient, Inc. - Correlogic Systems, Inc. - CytoCore (formerly Molecular Diagnostics, Inc.) - Cytogen Corporation (now EUSA Pharma) - diaDexus, Inc. - DiagnoCure, Inc. - Diagnostic Automation / Cortez Diagnostics, Inc. - DRG International, Inc. - Eisai Co., Ltd. - Enigma Diagnostics Ltd. - Epigenomics AG - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Gene Logic, Inc. - Gen-Probe, Inc. For more information visit http://www.researchandmarkets.com/research/xg...diagnostic
EXAS: 10.00 (-0.84), AFFX: 14.01 (+0.02), CPHD: 28.77 (-1.02)
DiagnoCure announces third quarter 2015 results
PR Newswire - Fri Sep 11, 6:30AM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today reported financial and operational results for the third quarter ended July 31, 2015. The Corporation announced a net loss of $274,005 or $0.01 per share for this quarter. At the end of the quarter, cash and temporary investments stood at $1,231,626. Operating expenses decreased by $250,683, to $406,846 for the third quarter of 2015 from $657,529 for the same period of 2014. The net loss before non-cash elements decreased by 54%, from $406,853 for the third quarter of 2014 to $186,335 for the same period of 2015. These decreases are attributable primarily to the reduction of operating expenses implemented in the first quarter of 2015. CUR.TO: 0.02 (+0.01)
DiagnoCure announces second quarter 2015 results and restructures its Board of directors
CNW Group - Fri Jun 12, 6:30AM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today reported financial and operational results for the second quarter ended April 30, 2015. The Corporation announced a net loss of $567,991 or $0.01 per share for this quarter. At the end of the quarter, cash and temporary investments stood at $1,574,957. Operating expenses, before restructuring charges of $188,964, decreased by $158,278, to $508,812 for the second quarter of 2015 from $667,090 for the same period of 2014. The net loss before non-cash elements and restructuring charges decreased by a third, from $431,706 for the second quarter of 2014 to $289,228 for the same period of 2015. These decreases are attributable primarily to the reduction of operating expenses implemented in the first quarter of 2015. CUR.TO: 0.02 (+0.01)
DiagnoCure's new prostate cancer multimarker urine test featured at a recent press event of the American Urological Association
CNW Group - Wed May 20, 4:01PM CDT
DiagnoCure Inc. (TSX: CUR; OTCQX: DGCRF) (the "Corporation"
today reports that the results of the prospective trial on its prostate cancer panel (PCP) urine test were well received by the urologist community attending the 2015 Annual Meeting of the American Urological Association (AUA) held from May 15 to May 19 in New Orleans, Louisiana. CUR.TO: 0.02 (+0.01)
DiagnoCure announces results of its Annual and General Meeting of shareholders
CNW Group - Thu Apr 30, 5:30PM CDT
DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today announced that its shareholders have approved all resolutions presented to them in the Management Proxy Circular dated March 5, 2015 and put forth for vote during the shareholders meeting held today in Montreal. CUR.TO: 0.02 (+0.01)
